Top stories in hematology/oncology: Cancer patients need simple language, most adults lack cancer prevention knowledge
Click Here to Manage Email Alerts
The top story in hematology/oncology last week discussed the importance of using simple, common language while communicating with patients to help them understand their cancer treatment.
Another top story was about survey results from the American Society of Clinical Oncology that showed 57% of adults in the United States were concerned about developing cancer in their lifetime, but only 24% incorporated cancer prevention practices in their daily lives.
Comprehensive cancer care requires a common, simple language
With the emergence of targeted treatment options, patients may need to understand the oncology lexicon now more than ever to help make decisions about their care. Others might argue that it is the job of clinicians to present options in a more easily understandable manner for patients. Read more.
ASCO survey: 24% of Americans incorporate cancer prevention into daily lives
Most Americans lack knowledge of best cancer prevention practices, the dangers of e-cigarettes and available end-of-life care despite an abundance of published data, according to results of ASCO’s third annual Cancer Opinions Survey. Read more.
10 important updates for Lung Cancer Awareness Month
In conjunction with Lung Cancer Awareness Month, HemOnc Today and Healio.com present 10 important updates in lung cancer diagnosis, treatment and prevention that may be relevant to your practice. Read more.
Phase 3 trial of pancreatic cancer therapy misses primary endpoint
A phase 3 trial designed to assess an investigational drug for first-line treatment of metastatic pancreatic cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer. Read more.
New treatment approaches induce responses in unresectable intrahepatic cholangiocarcinoma
Chemotherapy combined with hepatic arterial infusion of floxuridine or with selective internal radiotherapy induced antitumor activity among patients with unresectable intrahepatic cholangiocarcinoma, according to results of separate phase 2 studies published in JAMA Oncology. Read more.